

Resource Summary Report

Generated by [ASWG](#) on Aug 9, 2026

Brilliant Violet 421(TM) anti-mouse/rat/human CD27

RRID:AB_2565547

Type: Antibody

Proper Citation

BioLegend Cat# 124223, RRID:AB_2565547

Antibody Information

URL: http://antibodyregistry.org/AB_2565547

Proper Citation: BioLegend Cat# 124223, RRID:AB_2565547

Target Antigen: CD27

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 421(TM) anti-mouse/rat/human CD27

Description: This monoclonal targets CD27

Target Organism: rat, mouse, human

Clone ID: Clone LG.3A10

Antibody ID: AB_2565547

Vendor: BioLegend

Catalog Number: 124223

Record Creation Time: 20250820T000330+0000

Record Last Update: 20250820T071433+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-mouse/rat/human CD27.

No alerts have been found for Brilliant Violet 421(TM) anti-mouse/rat/human CD27.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Witt LT, et al. (2024) Streptococcus agalactiae and Escherichia coli induce distinct effector ?? T cell responses during neonatal sepsis. iScience, 27(5), 109669.

Andrews LP, et al. (2024) LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-?-dependent anti-tumor immunity. Cell, 187(16), 4355.

Dupraz L, et al. (2021) Gut microbiota-derived short-chain fatty acids regulate IL-17 production by mouse and human intestinal ?? T cells. Cell reports, 36(1), 109332.

Flommersfeld S, et al. (2021) Fate mapping of single NK cells identifies a type 1 innate lymphoid-like lineage that bridges innate and adaptive recognition of viral infection. Immunity, 54(10), 2288.

Frost JN, et al. (2021) Hepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection. Med (New York, N.Y.), 2(2), 164.

Sagnella SM, et al. (2020) Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. Cancer cell, 37(3), 354.